Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Brazil’s largest private lender, may increase provisions for company loan defaults in 2015 due to a corruption scandal at state-run oil firm Petrobras that has implicated several major construction firms, the bank’s senior vice president for risk and compliance said.On Friday shares of Itau Unibanco Holding SA (ADR) (NYSE:ITUB) closed at $13.15. Company’s sales growth for last 5 years was 14.60% and EPS growth for next 5 years is recorded as 17.48%.
Golar LNG Partners LP (NASDAQ:GMLP) announced the pricing of an underwritten secondary offering of 7,170,000 common units representing limited partner interests in Golar LNG Partners LP (“Golar Partners” or the “Partnership”) offered by Golar (the “Offering”) at a price of $29.90 per unit. Golar LNG Partners LP (NASDAQ:GMLP) in last trading activity decreased -10.93% to close at $27.71. Company weekly performance is -13.22% while its quarterly performance stands at -17.14%. Golar LNG Partners LP (NASDAQ:GMLP) is -28.46% away from its 52 week high.
MPLX LP (NYSE:MPLX) a master limited partnership sponsored by Marathon Petroleum Corporation will host a conference call on Wednesday, Feb. 4, 2015, at 2 p.m. EST to discuss 2014 fourth-quarter and full-year financial results, which will be released earlier that day, and to provide an update on partnership operations. On last trading day MPLX LP (NYSE:MPLX) advanced 1.57% to close at $72.67. Its volatility for the week is 5.63% while volatility for the month is 5.04%. MPLX LP (NYSE:MPLX) monthly performance is 17.49%.
Pharmacyclics Inc. (NASDAQ:PCYC) announced encouraging data on its oncology drug, Imbruvica. It was found that the use of Imbruvica in treatment-naive and previously treated patients suffering from chronic lymphocytic leukemia (CLL) resulted in a significant response rate, with 92% of high-risk CLL patients with deletion 17p (del 17p) or tumor protein 53 achieving an objective response. Pharmacyclics Inc. (NASDAQ:PCYC) has 0.40% insider ownership while its institutional ownership stands at 76.30%. In last trading activity company’s stock closed at $124.20.
On January 8, Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced that its lead drug candidate, selinexor (KPT-330), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Orphan designation was created to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases. On last trading day Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) advanced 0.09% to close at $32.04. Its volatility for the week is 5.62% while volatility for the month is 7.53%. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) monthly performance is -22.50%.